Apellis Pharmaceuticals, Inc. (APLS) is a publicly traded company in the Healthcare sector, operating within the Biotechnology industry. The company is headquartered in Waltham, MA, United States. The current CEO is Cedric Francois.
APLS has IPO date of 2017-11-09, 705 full-time employees, listed on the NASDAQ Global Select, a market capitalization of $5.22B.
Apellis Pharmaceuticals, Inc. is a commercial-stage biopharmaceutical company focused on discovering, developing, and commercializing therapeutic compounds that inhibit the complement system to treat autoimmune and inflammatory diseases. The company's lead product, pegcetacoplan, is in Phase III clinical trials for geographic atrophy in age-related macular degeneration and paroxysmal nocturnal hemoglobinuria, with the approved product EMPAVELI addressing multiple rare hematologic, nephrologic, and neurologic indications. Apellis maintains a robust pipeline including APL-2006, a bispecific C3 and VEGF inhibitor, and APL-1030, a C3 inhibitor for neurodegenerative diseases, supported by strategic collaborations with Swedish Orphan Biovitrum AB and Beam Therapeutics. Founded in 2009 and headquartered in Waltham, Massachusetts, the company is advancing complement-inhibition science across multiple therapeutic areas with significant unmet medical needs.
